Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study
Identifieur interne : 005632 ( Istex/Corpus ); précédent : 005631; suivant : 005633Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study
Auteurs : Jean-Claude Horiot Dijon ; François Lipinski Bayonne ; Simon Schraub Besançon ; Catherine Maulard-Durdux Paris St Louis ; René Jean Bensadoun Nice ; Jean Michel Ardiet Lyon-Sud ; Michel Bolla Grenoble ; Yvan Coscas Boulogne ; François Baillet Paris Pitié-Salpétrière ; Bernard Coche-Dequéant Lille ; Michel Urbajtel Argenteuil ; Xavier Montbarbon Lyon Léon Bérard ; Sylvain Bourdin Nantes ; Pierre Wibault Villejuif ; Marc Alfonsi Avignon ; Gilles Calais Tours ; Patrick Desprez Vannes ; Françoise Pene Paris Tenon ; Michel Lapeyre Nancy ; Jens Vinke ; Jean Maral Chiron B. V. The NetherlandsSource :
- Radiotherapy and Oncology [ 0167-8140 ] ; 2000.
English descriptors
- KwdEn :
- Action mechanism, Baseline, Baseline characteristics, Centre, Daily dose, Ectopic glands, Eligible patients, Elsevier science ireland, Favourable, Favourable group, Favourable groups, Food ingestion, Functional improvement, Further treatment, Gland, Good tolerance, Horiot, Hydrochloride, Neck cancer, Neck cancers, Oncology, Oral pilocarpine, Pilocarpine, Pilocarpine hydrochloride, Placebo, Placebo effect, Placebo group, Post radiation, Previous history, Radiation group, Radiation therapy, Radiotherapy, Radiotherapy parameters, Responder, Response rate, Salagen, Salivary, Salivary flow measurement, Salivary glands, Severe xerostomia, Side effects, Solid food ingestion, Target volume, Tissular damage, Toxicity, Unfavourable, Unfavourable group, Xerostomia, Xerostomia status, Xerostomia symptoms.
- Teeft :
- Action mechanism, Baseline, Baseline characteristics, Centre, Daily dose, Ectopic glands, Eligible patients, Elsevier science ireland, Favourable, Favourable group, Favourable groups, Food ingestion, Functional improvement, Further treatment, Gland, Good tolerance, Horiot, Hydrochloride, Neck cancer, Neck cancers, Oncology, Oral pilocarpine, Pilocarpine, Pilocarpine hydrochloride, Placebo, Placebo effect, Placebo group, Post radiation, Previous history, Radiation group, Radiation therapy, Radiotherapy, Radiotherapy parameters, Responder, Response rate, Salagen, Salivary, Salivary glands, Severe xerostomia, Side effects, Solid food ingestion, Target volume, Tissular damage, Toxicity, Unfavourable, Unfavourable group, Xerostomia, Xerostomia status, Xerostomia symptoms.
Abstract
Abstract: Background and purpose: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters. Materials and methods: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks. Results: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders. Conclusions: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.
Url:
DOI: 10.1016/S0167-8140(99)00018-3
Links to Exploration step
ISTEX:AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title><author><name sortKey="Horiot Dijon, Jean Claude" sort="Horiot Dijon, Jean Claude" uniqKey="Horiot Dijon J" first="Jean-Claude" last="Horiot Dijon">Jean-Claude Horiot Dijon</name></author><author><name sortKey="Lipinski Bayonne, Francois" sort="Lipinski Bayonne, Francois" uniqKey="Lipinski Bayonne F" first="François" last="Lipinski Bayonne">François Lipinski Bayonne</name></author><author><name sortKey="Schraub Besancon, Simon" sort="Schraub Besancon, Simon" uniqKey="Schraub Besancon S" first="Simon" last="Schraub Besançon">Simon Schraub Besançon</name></author><author><name sortKey="Maulard Durdux Paris St Louis, Catherine" sort="Maulard Durdux Paris St Louis, Catherine" uniqKey="Maulard Durdux Paris St Louis C" first="Catherine" last="Maulard-Durdux Paris St Louis">Catherine Maulard-Durdux Paris St Louis</name></author><author><name sortKey="Bensadoun Nice, Rene Jean" sort="Bensadoun Nice, Rene Jean" uniqKey="Bensadoun Nice R" first="René Jean" last="Bensadoun Nice">René Jean Bensadoun Nice</name></author><author><name sortKey="Ardiet Lyon Sud, Jean Michel" sort="Ardiet Lyon Sud, Jean Michel" uniqKey="Ardiet Lyon Sud J" first="Jean Michel" last="Ardiet Lyon-Sud">Jean Michel Ardiet Lyon-Sud</name></author><author><name sortKey="Bolla Grenoble, Michel" sort="Bolla Grenoble, Michel" uniqKey="Bolla Grenoble M" first="Michel" last="Bolla Grenoble">Michel Bolla Grenoble</name></author><author><name sortKey="Coscas Boulogne, Yvan" sort="Coscas Boulogne, Yvan" uniqKey="Coscas Boulogne Y" first="Yvan" last="Coscas Boulogne">Yvan Coscas Boulogne</name></author><author><name sortKey="Baillet Paris Pitie Salpetriere, Francois" sort="Baillet Paris Pitie Salpetriere, Francois" uniqKey="Baillet Paris Pitie Salpetriere F" first="François" last="Baillet Paris Pitié-Salpétrière">François Baillet Paris Pitié-Salpétrière</name></author><author><name sortKey="Coche Dequeant Lille, Bernard" sort="Coche Dequeant Lille, Bernard" uniqKey="Coche Dequeant Lille B" first="Bernard" last="Coche-Dequéant Lille">Bernard Coche-Dequéant Lille</name></author><author><name sortKey="Urbajtel Argenteuil, Michel" sort="Urbajtel Argenteuil, Michel" uniqKey="Urbajtel Argenteuil M" first="Michel" last="Urbajtel Argenteuil">Michel Urbajtel Argenteuil</name></author><author><name sortKey="Montbarbon Lyon Leon Berard, Xavier" sort="Montbarbon Lyon Leon Berard, Xavier" uniqKey="Montbarbon Lyon Leon Berard X" first="Xavier" last="Montbarbon Lyon Léon Bérard">Xavier Montbarbon Lyon Léon Bérard</name></author><author><name sortKey="Bourdin Nantes, Sylvain" sort="Bourdin Nantes, Sylvain" uniqKey="Bourdin Nantes S" first="Sylvain" last="Bourdin Nantes">Sylvain Bourdin Nantes</name></author><author><name sortKey="Wibault Villejuif, Pierre" sort="Wibault Villejuif, Pierre" uniqKey="Wibault Villejuif P" first="Pierre" last="Wibault Villejuif">Pierre Wibault Villejuif</name></author><author><name sortKey="Alfonsi Avignon, Marc" sort="Alfonsi Avignon, Marc" uniqKey="Alfonsi Avignon M" first="Marc" last="Alfonsi Avignon">Marc Alfonsi Avignon</name></author><author><name sortKey="Calais Tours, Gilles" sort="Calais Tours, Gilles" uniqKey="Calais Tours G" first="Gilles" last="Calais Tours">Gilles Calais Tours</name></author><author><name sortKey="Desprez Vannes, Patrick" sort="Desprez Vannes, Patrick" uniqKey="Desprez Vannes P" first="Patrick" last="Desprez Vannes">Patrick Desprez Vannes</name></author><author><name sortKey="Pene Paris Tenon, Francoise" sort="Pene Paris Tenon, Francoise" uniqKey="Pene Paris Tenon F" first="Françoise" last="Pene Paris Tenon">Françoise Pene Paris Tenon</name></author><author><name sortKey="Lapeyre Nancy, Michel" sort="Lapeyre Nancy, Michel" uniqKey="Lapeyre Nancy M" first="Michel" last="Lapeyre Nancy">Michel Lapeyre Nancy</name></author><author><name sortKey="Vinke, Jens" sort="Vinke, Jens" uniqKey="Vinke J" first="Jens" last="Vinke">Jens Vinke</name></author><author><name sortKey="Maral Chiron B V The Netherlands, Jean" sort="Maral Chiron B V The Netherlands, Jean" uniqKey="Maral Chiron B V The Netherlands J" first="Jean" last="Maral Chiron B. V. The Netherlands">Jean Maral Chiron B. V. The Netherlands</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0167-8140(99)00018-3</idno><idno type="url">https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">005632</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005632</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title><author><name sortKey="Horiot Dijon, Jean Claude" sort="Horiot Dijon, Jean Claude" uniqKey="Horiot Dijon J" first="Jean-Claude" last="Horiot Dijon">Jean-Claude Horiot Dijon</name></author><author><name sortKey="Lipinski Bayonne, Francois" sort="Lipinski Bayonne, Francois" uniqKey="Lipinski Bayonne F" first="François" last="Lipinski Bayonne">François Lipinski Bayonne</name></author><author><name sortKey="Schraub Besancon, Simon" sort="Schraub Besancon, Simon" uniqKey="Schraub Besancon S" first="Simon" last="Schraub Besançon">Simon Schraub Besançon</name></author><author><name sortKey="Maulard Durdux Paris St Louis, Catherine" sort="Maulard Durdux Paris St Louis, Catherine" uniqKey="Maulard Durdux Paris St Louis C" first="Catherine" last="Maulard-Durdux Paris St Louis">Catherine Maulard-Durdux Paris St Louis</name></author><author><name sortKey="Bensadoun Nice, Rene Jean" sort="Bensadoun Nice, Rene Jean" uniqKey="Bensadoun Nice R" first="René Jean" last="Bensadoun Nice">René Jean Bensadoun Nice</name></author><author><name sortKey="Ardiet Lyon Sud, Jean Michel" sort="Ardiet Lyon Sud, Jean Michel" uniqKey="Ardiet Lyon Sud J" first="Jean Michel" last="Ardiet Lyon-Sud">Jean Michel Ardiet Lyon-Sud</name></author><author><name sortKey="Bolla Grenoble, Michel" sort="Bolla Grenoble, Michel" uniqKey="Bolla Grenoble M" first="Michel" last="Bolla Grenoble">Michel Bolla Grenoble</name></author><author><name sortKey="Coscas Boulogne, Yvan" sort="Coscas Boulogne, Yvan" uniqKey="Coscas Boulogne Y" first="Yvan" last="Coscas Boulogne">Yvan Coscas Boulogne</name></author><author><name sortKey="Baillet Paris Pitie Salpetriere, Francois" sort="Baillet Paris Pitie Salpetriere, Francois" uniqKey="Baillet Paris Pitie Salpetriere F" first="François" last="Baillet Paris Pitié-Salpétrière">François Baillet Paris Pitié-Salpétrière</name></author><author><name sortKey="Coche Dequeant Lille, Bernard" sort="Coche Dequeant Lille, Bernard" uniqKey="Coche Dequeant Lille B" first="Bernard" last="Coche-Dequéant Lille">Bernard Coche-Dequéant Lille</name></author><author><name sortKey="Urbajtel Argenteuil, Michel" sort="Urbajtel Argenteuil, Michel" uniqKey="Urbajtel Argenteuil M" first="Michel" last="Urbajtel Argenteuil">Michel Urbajtel Argenteuil</name></author><author><name sortKey="Montbarbon Lyon Leon Berard, Xavier" sort="Montbarbon Lyon Leon Berard, Xavier" uniqKey="Montbarbon Lyon Leon Berard X" first="Xavier" last="Montbarbon Lyon Léon Bérard">Xavier Montbarbon Lyon Léon Bérard</name></author><author><name sortKey="Bourdin Nantes, Sylvain" sort="Bourdin Nantes, Sylvain" uniqKey="Bourdin Nantes S" first="Sylvain" last="Bourdin Nantes">Sylvain Bourdin Nantes</name></author><author><name sortKey="Wibault Villejuif, Pierre" sort="Wibault Villejuif, Pierre" uniqKey="Wibault Villejuif P" first="Pierre" last="Wibault Villejuif">Pierre Wibault Villejuif</name></author><author><name sortKey="Alfonsi Avignon, Marc" sort="Alfonsi Avignon, Marc" uniqKey="Alfonsi Avignon M" first="Marc" last="Alfonsi Avignon">Marc Alfonsi Avignon</name></author><author><name sortKey="Calais Tours, Gilles" sort="Calais Tours, Gilles" uniqKey="Calais Tours G" first="Gilles" last="Calais Tours">Gilles Calais Tours</name></author><author><name sortKey="Desprez Vannes, Patrick" sort="Desprez Vannes, Patrick" uniqKey="Desprez Vannes P" first="Patrick" last="Desprez Vannes">Patrick Desprez Vannes</name></author><author><name sortKey="Pene Paris Tenon, Francoise" sort="Pene Paris Tenon, Francoise" uniqKey="Pene Paris Tenon F" first="Françoise" last="Pene Paris Tenon">Françoise Pene Paris Tenon</name></author><author><name sortKey="Lapeyre Nancy, Michel" sort="Lapeyre Nancy, Michel" uniqKey="Lapeyre Nancy M" first="Michel" last="Lapeyre Nancy">Michel Lapeyre Nancy</name></author><author><name sortKey="Vinke, Jens" sort="Vinke, Jens" uniqKey="Vinke J" first="Jens" last="Vinke">Jens Vinke</name></author><author><name sortKey="Maral Chiron B V The Netherlands, Jean" sort="Maral Chiron B V The Netherlands, Jean" uniqKey="Maral Chiron B V The Netherlands J" first="Jean" last="Maral Chiron B. V. The Netherlands">Jean Maral Chiron B. V. The Netherlands</name></author></analytic><monogr></monogr><series><title level="j">Radiotherapy and Oncology</title><title level="j" type="abbrev">RADION</title><idno type="ISSN">0167-8140</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">55</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="233">233</biblScope><biblScope unit="page" to="239">239</biblScope></imprint><idno type="ISSN">0167-8140</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0167-8140</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action mechanism</term><term>Baseline</term><term>Baseline characteristics</term><term>Centre</term><term>Daily dose</term><term>Ectopic glands</term><term>Eligible patients</term><term>Elsevier science ireland</term><term>Favourable</term><term>Favourable group</term><term>Favourable groups</term><term>Food ingestion</term><term>Functional improvement</term><term>Further treatment</term><term>Gland</term><term>Good tolerance</term><term>Horiot</term><term>Hydrochloride</term><term>Neck cancer</term><term>Neck cancers</term><term>Oncology</term><term>Oral pilocarpine</term><term>Pilocarpine</term><term>Pilocarpine hydrochloride</term><term>Placebo</term><term>Placebo effect</term><term>Placebo group</term><term>Post radiation</term><term>Previous history</term><term>Radiation group</term><term>Radiation therapy</term><term>Radiotherapy</term><term>Radiotherapy parameters</term><term>Responder</term><term>Response rate</term><term>Salagen</term><term>Salivary</term><term>Salivary flow measurement</term><term>Salivary glands</term><term>Severe xerostomia</term><term>Side effects</term><term>Solid food ingestion</term><term>Target volume</term><term>Tissular damage</term><term>Toxicity</term><term>Unfavourable</term><term>Unfavourable group</term><term>Xerostomia</term><term>Xerostomia status</term><term>Xerostomia symptoms</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Action mechanism</term><term>Baseline</term><term>Baseline characteristics</term><term>Centre</term><term>Daily dose</term><term>Ectopic glands</term><term>Eligible patients</term><term>Elsevier science ireland</term><term>Favourable</term><term>Favourable group</term><term>Favourable groups</term><term>Food ingestion</term><term>Functional improvement</term><term>Further treatment</term><term>Gland</term><term>Good tolerance</term><term>Horiot</term><term>Hydrochloride</term><term>Neck cancer</term><term>Neck cancers</term><term>Oncology</term><term>Oral pilocarpine</term><term>Pilocarpine</term><term>Pilocarpine hydrochloride</term><term>Placebo</term><term>Placebo effect</term><term>Placebo group</term><term>Post radiation</term><term>Previous history</term><term>Radiation group</term><term>Radiation therapy</term><term>Radiotherapy</term><term>Radiotherapy parameters</term><term>Responder</term><term>Response rate</term><term>Salagen</term><term>Salivary</term><term>Salivary glands</term><term>Severe xerostomia</term><term>Side effects</term><term>Solid food ingestion</term><term>Target volume</term><term>Tissular damage</term><term>Toxicity</term><term>Unfavourable</term><term>Unfavourable group</term><term>Xerostomia</term><term>Xerostomia status</term><term>Xerostomia symptoms</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Background and purpose: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters. Materials and methods: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks. Results: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders. Conclusions: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>xerostomia</json:string><json:string>pilocarpine</json:string><json:string>radiotherapy</json:string><json:string>pilocarpine hydrochloride</json:string><json:string>favourable</json:string><json:string>xerostomia status</json:string><json:string>placebo</json:string><json:string>horiot</json:string><json:string>salivary</json:string><json:string>unfavourable</json:string><json:string>toxicity</json:string><json:string>salagen</json:string><json:string>responder</json:string><json:string>oncology</json:string><json:string>side effects</json:string><json:string>salivary glands</json:string><json:string>neck cancers</json:string><json:string>favourable group</json:string><json:string>severe xerostomia</json:string><json:string>response rate</json:string><json:string>baseline</json:string><json:string>daily dose</json:string><json:string>radiotherapy parameters</json:string><json:string>solid food ingestion</json:string><json:string>centre</json:string><json:string>hydrochloride</json:string><json:string>radiation therapy</json:string><json:string>ectopic glands</json:string><json:string>target volume</json:string><json:string>tissular damage</json:string><json:string>eligible patients</json:string><json:string>neck cancer</json:string><json:string>post radiation</json:string><json:string>placebo effect</json:string><json:string>good tolerance</json:string><json:string>elsevier science ireland</json:string><json:string>previous history</json:string><json:string>baseline characteristics</json:string><json:string>food ingestion</json:string><json:string>placebo group</json:string><json:string>further treatment</json:string><json:string>xerostomia symptoms</json:string><json:string>unfavourable group</json:string><json:string>oral pilocarpine</json:string><json:string>radiation group</json:string><json:string>favourable groups</json:string><json:string>action mechanism</json:string><json:string>functional improvement</json:string><json:string>gland</json:string></teeft></keywords><author><json:item><name>Jean-Claude Horiot (Dijon)</name></json:item><json:item><name>François Lipinski (Bayonne)</name></json:item><json:item><name>Simon Schraub (Besançon)</name></json:item><json:item><name>Catherine Maulard-Durdux (Paris St Louis)</name></json:item><json:item><name>René Jean Bensadoun (Nice)</name></json:item><json:item><name>Jean Michel Ardiet (Lyon-Sud)</name></json:item><json:item><name>Michel Bolla (Grenoble)</name></json:item><json:item><name>Yvan Coscas (Boulogne)</name></json:item><json:item><name>François Baillet (Paris Pitié-Salpétrière)</name></json:item><json:item><name>Bernard Coche-Dequéant (Lille)</name></json:item><json:item><name>Michel Urbajtel (Argenteuil)</name></json:item><json:item><name>Xavier Montbarbon (Lyon Léon Bérard)</name></json:item><json:item><name>Sylvain Bourdin (Nantes)</name></json:item><json:item><name>Pierre Wibault (Villejuif)</name></json:item><json:item><name>Marc Alfonsi (Avignon)</name></json:item><json:item><name>Gilles Calais (Tours)</name></json:item><json:item><name>Patrick Desprez (Vannes)</name></json:item><json:item><name>Françoise Pene (Paris Tenon)</name></json:item><json:item><name>Michel Lapeyre (Nancy)</name></json:item><json:item><name>Jens Vinke</name></json:item><json:item><name>Jean Maral (Chiron B.V. The Netherlands)</name></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Xerostomia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Salivary glands</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Salivary flow measurement</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pilocarpine</value></json:item></subject><arkIstex>ark:/67375/6H6-D49SVSCS-M</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Background and purpose: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters. Materials and methods: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks. Results: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders. Conclusions: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>224</abstractWordCount><abstractCharCount>1487</abstractCharCount><keywordCount>4</keywordCount><score>8.532</score><pdfWordCount>3844</pdfWordCount><pdfCharCount>23772</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595 x 794 pts</pdfPageSize></qualityIndicators><title>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title><pmid><json:string>11041775</json:string></pmid><pii><json:string>S0167-8140(99)00018-3</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Radiotherapy and Oncology</title><language><json:string>unknown</json:string></language><publicationDate>2000</publicationDate><issn><json:string>0167-8140</json:string></issn><pii><json:string>S0167-8140(00)X0065-5</json:string></pii><volume>55</volume><issue>3</issue><pages><first>233</first><last>239</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>From June 1995 to December 1995</json:string><json:string>2000</json:string><json:string>1986</json:string><json:string>From June 1995 to February 1996</json:string><json:string>1993</json:string></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Pierre Wibault</json:string><json:string>Marc Alfonsi</json:string><json:string>Paris Nancy</json:string><json:string>Calais Dr</json:string><json:string>Leveque</json:string><json:string>Cochedequeant Dr</json:string><json:string>CHU Michallon</json:string><json:string>Bernard Coche-Dequeant</json:string><json:string>CHU Minjoz</json:string><json:string>Michel Urbajtel</json:string><json:string>Maularddurdux Dr</json:string><json:string>Rene Jean</json:string><json:string>Bayonne</json:string><json:string>Patrick Desprez</json:string><json:string>Yvan Coscas</json:string><json:string>Xavier Montbarbon</json:string><json:string>R. Gauducheau</json:string><json:string>Lipinski Pr</json:string><json:string>Paris Pitie-Salpetriere</json:string><json:string>Jean Michel</json:string><json:string>Jean Maral</json:string><json:string>Michel Lapeyre</json:string><json:string>Pene Dr</json:string><json:string>O. Lambret</json:string><json:string>Francois Baillet</json:string><json:string>Leon Berard</json:string><json:string>G. Roussy</json:string><json:string>Wibault Dr</json:string><json:string>Sylvain Bourdin</json:string><json:string>Coscas Pr</json:string><json:string>Michel Bolla</json:string><json:string>Jens Vinke</json:string><json:string>Montbarbon Dr</json:string><json:string>Simon Schraub</json:string><json:string>Catherine Maulard-Durdux</json:string><json:string>Paris Tenon</json:string><json:string>A. Vautrin</json:string></persName><placeName><json:string>Avignon</json:string><json:string>Bayonne</json:string><json:string>Ste Catherine</json:string><json:string>Grenoble</json:string><json:string>Toxicity</json:string><json:string>St Yves</json:string><json:string>Nice</json:string><json:string>Vannes</json:string><json:string>Argenteuil</json:string><json:string>Nantes</json:string><json:string>Dijon</json:string><json:string>Calais</json:string><json:string>Lille</json:string><json:string>Lyon</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[6]</json:string><json:string>[3,4]</json:string><json:string>Johnson et al. [8]</json:string><json:string>[7]</json:string><json:string>[1,10]</json:string><json:string>[9]</json:string><json:string>C. Horiot et al.</json:string><json:string>[2]</json:string><json:string>Fox et al. [5]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-D49SVSCS-M</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - radiology, nuclear medicine & medical imaging</json:string><json:string>2 - oncology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - oncology & carcinogenesis</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Radiology Nuclear Medicine and imaging</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0167-8140(99)00018-3</json:string></doi><id>AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2000 Elsevier Science Ireland Ltd</p></availability><date>2000</date></publicationStmt><notesStmt><note type="content">Fig. 1: Evaluation of solid food ingestion: all patients at baseline and week 12 (n = 145).</note><note type="content">Fig. 2: Evaluation of psychological impact of xerostomia: all patients at baseline and week 12 (n = 145).</note><note type="content">Table 1: From June 1995 to December 1995: 156 eligible patients from 19 participating centres</note><note type="content">Table 2: Baseline characteristics (n=156)</note><note type="content">Table 3: Side effects (n=156, all who started treatment)a,b,c</note><note type="content">Table 4: Summary of primary reasons for study termination at week 12</note><note type="content">Table 5: Improvement of xerostomia status per radiation group at week 12 (n=145)</note><note type="content">Table 6: Evolution of xerostomia status from week 12 to week 24</note><note type="content">Table 7: Improvement of xerostomia status per radiation subgroup at week 12</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title><author xml:id="author-0000"><persName><forename type="first">Jean-Claude</forename><surname>Horiot (Dijon)</surname></persName></author><author xml:id="author-0001"><persName><forename type="first">François</forename><surname>Lipinski (Bayonne)</surname></persName></author><author xml:id="author-0002"><persName><forename type="first">Simon</forename><surname>Schraub (Besançon)</surname></persName></author><author xml:id="author-0003"><persName><forename type="first">Catherine</forename><surname>Maulard-Durdux (Paris St Louis)</surname></persName></author><author xml:id="author-0004"><persName><forename type="first">René Jean</forename><surname>Bensadoun (Nice)</surname></persName></author><author xml:id="author-0005"><persName><forename type="first">Jean Michel</forename><surname>Ardiet (Lyon-Sud)</surname></persName></author><author xml:id="author-0006"><persName><forename type="first">Michel</forename><surname>Bolla (Grenoble)</surname></persName></author><author xml:id="author-0007"><persName><forename type="first">Yvan</forename><surname>Coscas (Boulogne)</surname></persName></author><author xml:id="author-0008"><persName><forename type="first">François</forename><surname>Baillet (Paris Pitié-Salpétrière)</surname></persName></author><author xml:id="author-0009"><persName><forename type="first">Bernard</forename><surname>Coche-Dequéant (Lille)</surname></persName></author><author xml:id="author-0010"><persName><forename type="first">Michel</forename><surname>Urbajtel (Argenteuil)</surname></persName></author><author xml:id="author-0011"><persName><forename type="first">Xavier</forename><surname>Montbarbon (Lyon Léon Bérard)</surname></persName></author><author xml:id="author-0012"><persName><forename type="first">Sylvain</forename><surname>Bourdin (Nantes)</surname></persName></author><author xml:id="author-0013"><persName><forename type="first">Pierre</forename><surname>Wibault (Villejuif)</surname></persName></author><author xml:id="author-0014"><persName><forename type="first">Marc</forename><surname>Alfonsi (Avignon)</surname></persName></author><author xml:id="author-0015"><persName><forename type="first">Gilles</forename><surname>Calais (Tours)</surname></persName></author><author xml:id="author-0016"><persName><forename type="first">Patrick</forename><surname>Desprez (Vannes)</surname></persName></author><author xml:id="author-0017"><persName><forename type="first">Françoise</forename><surname>Pene (Paris Tenon)</surname></persName></author><author xml:id="author-0018"><persName><forename type="first">Michel</forename><surname>Lapeyre (Nancy)</surname></persName></author><author xml:id="author-0019"><persName><forename type="first">Jens</forename><surname>Vinke</surname></persName></author><author xml:id="author-0020"><persName><forename type="first">Jean</forename><surname>Maral (Chiron B.V. The Netherlands)</surname></persName></author><idno type="istex">AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E</idno><idno type="DOI">10.1016/S0167-8140(99)00018-3</idno><idno type="PII">S0167-8140(99)00018-3</idno></analytic><monogr><title level="j">Radiotherapy and Oncology</title><title level="j" type="abbrev">RADION</title><idno type="pISSN">0167-8140</idno><idno type="PII">S0167-8140(00)X0065-5</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">55</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="233">233</biblScope><biblScope unit="page" to="239">239</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background and purpose: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters. Materials and methods: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks. Results: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders. Conclusions: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Xerostomia</term></item><item><term>Salivary glands</term></item><item><term>Salivary flow measurement</term></item><item><term>Pilocarpine</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998-12-16">Modified</change><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="gr1"></istex:entity><istex:entity SYSTEM="gr2" NDATA="IMAGE" name="gr2"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>RADION</jid><aid>2288</aid><ce:pii>S0167-8140(99)00018-3</ce:pii><ce:doi>10.1016/S0167-8140(99)00018-3</ce:doi><ce:copyright type="full-transfer" year="2000">Elsevier Science Ireland Ltd</ce:copyright></item-info><head><ce:title>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</ce:title><ce:author-group><ce:author><ce:given-name>Jean-Claude</ce:given-name><ce:surname>Horiot (Dijon)</ce:surname><ce:cross-ref refid="CORR1">*</ce:cross-ref></ce:author><ce:author><ce:given-name>François</ce:given-name><ce:surname>Lipinski (Bayonne)</ce:surname></ce:author><ce:author><ce:given-name>Simon</ce:given-name><ce:surname>Schraub (Besançon)</ce:surname></ce:author><ce:author><ce:given-name>Catherine</ce:given-name><ce:surname>Maulard-Durdux (Paris St Louis)</ce:surname></ce:author><ce:author><ce:given-name>René Jean</ce:given-name><ce:surname>Bensadoun (Nice)</ce:surname></ce:author><ce:author><ce:given-name>Jean Michel</ce:given-name><ce:surname>Ardiet (Lyon-Sud)</ce:surname></ce:author><ce:author><ce:given-name>Michel</ce:given-name><ce:surname>Bolla (Grenoble)</ce:surname></ce:author><ce:author><ce:given-name>Yvan</ce:given-name><ce:surname>Coscas (Boulogne)</ce:surname></ce:author><ce:author><ce:indexed-name>Baillet (Paris Pitie-Salpetriere)</ce:indexed-name><ce:given-name>François</ce:given-name><ce:surname>Baillet (Paris Pitié-Salpétrière)</ce:surname></ce:author><ce:author><ce:indexed-name>Coche-Dequeant (Lille)</ce:indexed-name><ce:given-name>Bernard</ce:given-name><ce:surname>Coche-Dequéant (Lille)</ce:surname></ce:author><ce:author><ce:given-name>Michel</ce:given-name><ce:surname>Urbajtel (Argenteuil)</ce:surname></ce:author><ce:author><ce:indexed-name>Montbarbon (Lyon Leon Berard)</ce:indexed-name><ce:given-name>Xavier</ce:given-name><ce:surname>Montbarbon (Lyon Léon Bérard)</ce:surname></ce:author><ce:author><ce:given-name>Sylvain</ce:given-name><ce:surname>Bourdin (Nantes)</ce:surname></ce:author><ce:author><ce:given-name>Pierre</ce:given-name><ce:surname>Wibault (Villejuif)</ce:surname></ce:author><ce:author><ce:given-name>Marc</ce:given-name><ce:surname>Alfonsi (Avignon)</ce:surname></ce:author><ce:author><ce:given-name>Gilles</ce:given-name><ce:surname>Calais (Tours)</ce:surname></ce:author><ce:author><ce:given-name>Patrick</ce:given-name><ce:surname>Desprez (Vannes)</ce:surname></ce:author><ce:author><ce:given-name>Françoise</ce:given-name><ce:surname>Pene (Paris Tenon)</ce:surname></ce:author><ce:author><ce:given-name>Michel</ce:given-name><ce:surname>Lapeyre (Nancy)</ce:surname></ce:author><ce:author><ce:given-name>Jens</ce:given-name><ce:surname>Vinke</ce:surname></ce:author><ce:author><ce:given-name>Jean</ce:given-name><ce:surname>Maral (Chiron B.V. The Netherlands)</ce:surname></ce:author><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Corresponding author. Radiation Therapy Department, Centre Georges-François Leclerc, B.P. 1544, 21034 Dijon Cedex, France</ce:text></ce:correspondence></ce:author-group><ce:date-received day="13" month="8" year="1998"></ce:date-received><ce:date-revised day="16" month="12" year="1998"></ce:date-revised><ce:date-accepted day="22" month="12" year="1998"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para><ce:italic>Background and purpose</ce:italic>: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters.</ce:simple-para><ce:simple-para><ce:italic>Materials and methods</ce:italic>: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks.</ce:simple-para><ce:simple-para><ce:italic>Results</ce:italic>: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders.</ce:simple-para><ce:simple-para><ce:italic>Conclusions</ce:italic>: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword" xml:lang="en"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Xerostomia</ce:text></ce:keyword><ce:keyword><ce:text>Salivary glands</ce:text></ce:keyword><ce:keyword><ce:text>Salivary flow measurement</ce:text></ce:keyword><ce:keyword><ce:text>Pilocarpine</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</title></titleInfo><name type="personal"><namePart type="given">Jean-Claude</namePart><namePart type="family">Horiot (Dijon)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Lipinski (Bayonne)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Simon</namePart><namePart type="family">Schraub (Besançon)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Catherine</namePart><namePart type="family">Maulard-Durdux (Paris St Louis)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">René Jean</namePart><namePart type="family">Bensadoun (Nice)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean Michel</namePart><namePart type="family">Ardiet (Lyon-Sud)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michel</namePart><namePart type="family">Bolla (Grenoble)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yvan</namePart><namePart type="family">Coscas (Boulogne)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Baillet (Paris Pitié-Salpétrière)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Coche-Dequéant (Lille)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michel</namePart><namePart type="family">Urbajtel (Argenteuil)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xavier</namePart><namePart type="family">Montbarbon (Lyon Léon Bérard)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sylvain</namePart><namePart type="family">Bourdin (Nantes)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Wibault (Villejuif)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Alfonsi (Avignon)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gilles</namePart><namePart type="family">Calais (Tours)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrick</namePart><namePart type="family">Desprez (Vannes)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Françoise</namePart><namePart type="family">Pene (Paris Tenon)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michel</namePart><namePart type="family">Lapeyre (Nancy)</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jens</namePart><namePart type="family">Vinke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean</namePart><namePart type="family">Maral (Chiron B.V. The Netherlands)</namePart><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><dateModified encoding="w3cdtf">1998-12-16</dateModified><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Background and purpose: The aim of the study was: (1) to confirm the action of pilocarpine hydrochloride (Salagen) against xerostomia; (2) to correlate the response to dose/volume radiotherapy parameters. Materials and methods: From June 1995 to February 1996, 156 patients with severe radiation induced xerostomia received pilocarpine hydrochloride orally, 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks. Results: One hundred and forty five patients are fully evaluable. Treatment compliance was 75%. Thirty eight patients (26%) stopped treatment before week 12 for acute intolerance (sweating, nausea, vomiting) or no response. No severe complication occurred. Ninety seven patients (67%) reported a significant relief of symptoms of xerostomia at 12 weeks. Within 12 weeks, the size of the subgroup with normal food intake almost doubled (13–24 patients) while the size of the subgroup with (nearly) impossible solid food ingestion decreased by 38% (47 vs. 29 patients). The impact on quality of life was considered important or very important by 77% of the responders. Conclusions: No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands; (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters; (3) all responders are identified at 12 weeks.</abstract><note type="content">Fig. 1: Evaluation of solid food ingestion: all patients at baseline and week 12 (n = 145).</note><note type="content">Fig. 2: Evaluation of psychological impact of xerostomia: all patients at baseline and week 12 (n = 145).</note><note type="content">Table 1: From June 1995 to December 1995: 156 eligible patients from 19 participating centres</note><note type="content">Table 2: Baseline characteristics (n=156)</note><note type="content">Table 3: Side effects (n=156, all who started treatment)a,b,c</note><note type="content">Table 4: Summary of primary reasons for study termination at week 12</note><note type="content">Table 5: Improvement of xerostomia status per radiation group at week 12 (n=145)</note><note type="content">Table 6: Evolution of xerostomia status from week 12 to week 24</note><note type="content">Table 7: Improvement of xerostomia status per radiation subgroup at week 12</note><subject lang="en"><genre>Keywords</genre><topic>Xerostomia</topic><topic>Salivary glands</topic><topic>Salivary flow measurement</topic><topic>Pilocarpine</topic></subject><relatedItem type="host"><titleInfo><title>Radiotherapy and Oncology</title></titleInfo><titleInfo type="abbreviated"><title>RADION</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">20000601</dateIssued></originInfo><identifier type="ISSN">0167-8140</identifier><identifier type="PII">S0167-8140(00)X0065-5</identifier><part><date>20000601</date><detail type="volume"><number>55</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="issue-pages"><start>203</start><end>333</end></extent><extent unit="pages"><start>233</start><end>239</end></extent></part></relatedItem><identifier type="istex">AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E</identifier><identifier type="ark">ark:/67375/6H6-D49SVSCS-M</identifier><identifier type="DOI">10.1016/S0167-8140(99)00018-3</identifier><identifier type="PII">S0167-8140(99)00018-3</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Ireland Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Elsevier Science Ireland Ltd, ©2000</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005632 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 005632 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:AD3035EEAD6D57D9DDEC2F69CF6F853F090BB88E
|texte= Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study
}}
| This area was generated with Dilib version V0.6.32. |  |